title: Incidence of dysthyroidism during interferon therapy in chronic hepatitis C.
abstract: Seventy-nine patients (40 males, 39 females) were enrolled in a prospective study of lymphoblastoid interferon-alpha (IFN), 3-5 MU three times weekly. They were randomly assigned to receive either 12 months of IFN therapy, or to 6 months of observation followed by 6 months of IFN therapy. The thyroid functional and immunological status was checked every other month during and after treatment. Before treatment, antithyroid antibodies were found in 6 patients (7.5%). Two were hypothyroid and were excluded from the study before starting IFN therapy. Seventy-seven patients received IFN therapy. Of these, thyroid abnormalities appeared in 6 (7.5%). Hyperthyroidism was observed in 3 patients. Two recovered within a few months, but 1 developed subsequent hypothyroidism. Hypothyroidism was observed in 2 patients. TSH blood values were persistently abnormal, but thyroid antibody levels remained increased and fluctuating. Thyroid function usually recovered within a few months; but 2 patients required hormonal therapy and 1 was treated with carbimazole. In 1 patient, a small thyroid papillary carcinoma was observed, but no evidence of relationship with the liver disease or with IFN therapy was found. In a patient with chronic hepatitis C, systematic thyroid assessment should be performed before initiating IFN therapy, including clinical examination, and measurement of TSH and anti-thyroperoxidase antibodies (TPO Ab). During treatment, a TSH assay every other month appears to be necessary and sufficient.
authors.affiliation: Department of Nuclear Medicine, Hôpital Beaujon, Clichy, France.
authors.forename: S
authors.initials: S
authors.lastname: Benelhadj
authors.forename: P
authors.initials: P
authors.lastname: Marcellin
authors.forename: C
authors.initials: C
authors.lastname: Castelnau
authors.forename: N
authors.initials: N
authors.lastname: Colas-Linhart
authors.forename: J P
authors.initials: JP
authors.lastname: Benhamou
authors.forename: S
authors.initials: S
authors.lastname: Erlinger
authors.forename: B
authors.initials: B
authors.lastname: Bok
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D006980:Hyperthyroidism / Q000139:chemically induced* / Q000276:immunology; D007037:Hypothyroidism / Q000139:chemically induced* / Q000276:immunology; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011863:Radioimmunoassay; D013954:Thyroglobulin / Q000276:immunology; D013961:Thyroid Gland / Q000187:drug effects / Q000276:immunology; D013972:Thyrotropin / Q000097:blood
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D013972:Thyrotropin; D013954:Thyroglobulin